Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases... Show more
ABIVAX Société Anonyme (ABVX) is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response for chronic inflammatory diseases. The stock dropped sharply in today's trading session, falling roughly 44.56% from the previous close of $129.69. The decline followed the release of topline results from the ABTECT trial, where the company reported that its lead candidate met key endpoints but a cancer signal emerged in the data.
The ABTECT trial evaluated obefazimod in patients with ulcerative colitis and demonstrated statistically significant improvements in remission rates and other secondary measures. Despite hitting these efficacy targets, the presence of a cancer signal prompted immediate market reaction. Investors weighed the positive clinical outcomes against the potential implications for the drug's development timeline and approvability.
Trading volume increased substantially compared with recent averages, reflecting heightened selling pressure. The move diverged from broader market indices, which showed more modest fluctuations. The stock broke below key technical support levels established in prior sessions, amplifying the downside momentum as stop-loss orders triggered.
Tickeron’s Trending AI Robots page showcases a curated selection of the platform’s strongest-performing AI trading bots under current market conditions. Tickeron provides access to hundreds of AI-driven bots that trade thousands of symbols across various strategies, timeframes, and performance metrics. The trending section highlights only those bots demonstrating the best results in the prevailing environment. Review the page to explore automated trading options suited to different market outlooks.
Investors will focus on the full dataset from the ABTECT trial and the upcoming maintenance-phase readout expected later in the second quarter. Regulatory feedback on the safety observations will be closely watched, as will any updates on the company’s development plans for obefazimod. Broader sector developments in inflammatory bowel disease treatments and overall biotech sentiment could influence near-term price action.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABVX's Aroon Indicator triggered a bullish signal on June 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 107 similar instances where the Aroon Indicator showed a similar pattern. In of the 107 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABVX's RSI Oscillator exited the oversold zone, of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 27 cases where ABVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ABVX as a result. In of 42 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +4 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVX advanced for three days, in of 168 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for ABVX turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at .
ABVX moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABVX crossed bearishly below the 50-day moving average on June 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.447) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ABVX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (192.308) is also within normal values, averaging (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology